Adam C Parslow
Overview
Explore the profile of Adam C Parslow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy
Parslow A, Clayton A, Lock P, Scott A
J Vis Exp
. 2018 Aug;
(138).
PMID: 30124657
Confocal microscopy provides an accessible methodology to capture sub-cellular interactions critical for the characterization and further development of pre-clinical agents labeled with fluorescent probes. With recent advancements in antibody based...
12.
Burvenich I, Parakh S, Parslow A, Lee S, Gan H, Scott A
AAPS J
. 2018 Mar;
20(2):43.
PMID: 29520671
The selection of therapeutic dose for the most effective treatment of tumours is an intricate interplay of factors. Molecular imaging with positron emission tomography (PET) or single-photon emission computed tomography...
13.
Parakh S, Gan H, Parslow A, Burvenich I, Burgess A, Scott A
Cancer Treat Rev
. 2017 Jul;
59:1-21.
PMID: 28715775
The development of HER2-directed monoclonal antibodies and tyrosine kinase inhibitors have provided benefits to cancer patients, as well as produced many insights into the biology of the ErbB receptor family....
14.
Parslow A, Parakh S, Lee F, Gan H, Scott A
Biomedicines
. 2017 May;
4(3).
PMID: 28536381
Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting...
15.
Coulson R, Liew S, Connelly A, Yee N, Deb S, Kumar B, et al.
Oncotarget
. 2017 Apr;
8(12):18640-18656.
PMID: 28416734
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE)...
16.
Algama M, Tasker E, Williams C, Parslow A, Bryson-Richardson R, Keith J
BMC Genomics
. 2017 Mar;
18(1):259.
PMID: 28347272
Background: Computational identification of non-coding RNAs (ncRNAs) is a challenging problem. We describe a genome-wide analysis using Bayesian segmentation to identify intronic elements highly conserved between three evolutionarily distant vertebrate...
17.
Burvenich I, Lee F, Guo N, Gan H, Rigopoulos A, Parslow A, et al.
Theranostics
. 2016 Dec;
6(12):2225-2234.
PMID: 27924159
DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific binding to DR5. DS-8273a is currently being used in...
18.
Parakh S, Parslow A, Gan H, Scott A
Expert Opin Drug Deliv
. 2015 Dec;
13(3):401-19.
PMID: 26654403
Introduction: Antibody-conjugated therapies (ACTs) combine the specificity of monoclonal antibodies to target cancer cells directly with highly potent payloads, often resulting in superior efficacy and/or reduced toxicity. This represents a...
19.
Sztal T, Zhao M, Williams C, Oorschot V, Parslow A, Giousoh A, et al.
Acta Neuropathol
. 2015 May;
130(3):389-406.
PMID: 25931053
Nemaline myopathy is characterized by muscle weakness and the presence of rod-like (nemaline) bodies. The genetic etiology of nemaline myopathy is becoming increasingly understood with mutations in ten genes now...
20.
Boglev Y, Badrock A, Trotter A, Du Q, Richardson E, Parslow A, et al.
PLoS Genet
. 2013 Feb;
9(2):e1003279.
PMID: 23408911
Ribosome biogenesis underpins cell growth and division. Disruptions in ribosome biogenesis and translation initiation are deleterious to development and underlie a spectrum of diseases known collectively as ribosomopathies. Here, we...